Flynn Sean C. sold 15,000 shares of Vericel Corp at $51.92 for −$779k on Nov 5, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Legal Officer
Chief Legal Officer
Filed Nov 6, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$778,800Shares × reported price
Shares traded
15,000Common Stock
Price per share
$51.92Reported price. Read footnotes for ranges.
% of reported position traded
88.29%This security and ownership context
Holdings after
1,990Direct
Trade date
Nov 5, 2026Sell
Filed
Nov 6, 2026, 4:05 PM ET1-day reporting delay
Accession
0001140361-26-042464Code S · Transaction 394645
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 16,990 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 5, 2026Option exercise15,000$16.25$243,750Trade 394644
Nov 5, 2026Option exercise15,000$0.00$0Trade 394646
3 transaction rows in this filing. Joint filers share the same rows.

VCEL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
VCEL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −27%1w ago −21%1d ago −21%
Returns since7d +4.3%30d90d180d1y

Footnotes in full

F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2025. F3: These options, representing the right to purchase 150,000 shares, became exercisable on November 4, 2020, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.